细胞周期相关蛋白激酶2 在结肠癌中的表达及临床意义
| 作者: |
1陈一思,
2易维
1 武汉市第一医院消化内科，武汉 430022 2 华中科技大学同济医学院附属同济医院综合科，武汉 430030 |
| 通讯: |
易维
Email: yiwei6660@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2018.09.003 |
摘要
目的：探索细胞周期相关蛋白激酶2(NIMA-related kinase 2，NEK2)在结肠癌中的表达及临床意义。方法：回顾性分析武汉市第一医院2012年11月至2015年5月间收治的120例结肠癌患者临床资料及随访情况。采用免疫组织化学法检测结肠癌组织与癌旁组织中NEK2的表达情况，依据结肠癌免疫组织化学结果分成NEK2高表达组和低表达组，卡方检验分析NEK2的表达与病理因素的关系，单因素及多因素分析影响总生存率及累计复发率的危险因素，Kaplan-Meier(K-M)法绘制生存曲线。结果：NEK2在结肠癌组织中的表达显著高于癌旁组织。NEK2高表达组与年龄(P=0.260)、性别(P=0.580)、肿瘤直径(P=0.522)、浆膜浸润(P=0.116)无关，而与肿瘤分化程度(P=0.021)、淋巴结转移(P=0.017)、AJCC分期(P=0.018)相关。AJCC分期及NEK2的表达为影响总生存率和累计复发率的独立影响因子。NEK2高表达组1，3年总生存率分别为33.4%，19%，NEK2低表达组1，3年总生存率为70.3%，35%，NEK2高表达组1，3年总生存率低于NEK2低表达组(P<0.05)；NEK2高表达组1， 3年累计复发率分别为69.7%，84.3%，NEK2低表达组1年累计复发率为35.8%，72.4%，NEK2高表达组1，3年累计复发率高于NEK2低表达组(P<0.05)。结论：NEK2在结肠癌组织中高表达，NEK2高表达与恶性临床病理因素相关，NEK2是影响结肠癌患者预后的独立危险因素。
关键词：
结肠癌；细胞周期相关蛋白激酶2；预后；临床意义
Expression and clinical significance of NIMA-related kinase 2 protein in colon cancer
CorrespondingAuthor: YI Wei Email: yiwei6660@126.com
DOI: 10.3978/j.issn.2095-6959.2018.09.003
Abstract
Objective: To assess the expression profile of NIMA-related kinase 2 (NEK2) in colon cancer and its clinical significance. Methods: One hundred and twenty patients with colon cancer were retrospectively collected in the First Hospital of Wuhan from January 2012 to May 2015. Immunohistochemical staining was used to measure the expression of NEK2 protein in colon cancer tissues and paratumor tissues. The patients were divided into an NEK2 over-express group and an NEK2 low-express group, according to the express level of NEK2 in colon cancer tissue. Chi-square test was performed to reveal the relationship between NEK2 expression and clinicopathological features. COX proportional hazard models were used to estimate the univariate and multivariate analyses. The Kaplan-Meier (K-M) curve was used to describe the overall survival. Results: NEK2 expression level was obviously higher in colorectal cancer tissues than paratumor tissues. NEK2 high express group was not correlated with age (P=0.260), sex (P=0.580), tumor diameter (P=0.522), serosal invasion (P=0.116), while significantly correlate with tumor differentiation (P=0.021), lymphatic metastasis (P=0.017), AJCC staging (P=0.018). AJCC staging and NEK2 expression was independent influence factor of overall survival rate and cumulative recurrence rate. The 1- and 3-year overall survival rate of the NEK2 high-express group was 33.4% and 19%, respectively, while 70.3% and 35% in the NEK2 low-express group, the 1- and 3-year overall survival rate of NEK2 high-express group was significantly lower than that in the NEK2 low-express group (P<0.05). The 1- and 3-year cumulative recurrence rate of NEK2 high-express group was 69.7% and 84.3%, respectively, while 35.8% and 72.4% in NEK2 low-express group, the 1- and 3-year cumulative recurrence rate of the NEK2 high-express group was significantly higher than that in the NEK2 low-express group (P<0.05). Conclusion: NEK2 is high expressed in colorectal cancer tissues. Over-expression of NEK2 is closely related to malignant clinicopathological factors. NEK2 can act as an independent risk factor for prognosis in patients with colon cancer.
Keywords：
colon cancer; NIMA-related kinase 2; prognosis; clinical significance